+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The hepatix extracorporeal liver assist device: Initial clinical experience



The hepatix extracorporeal liver assist device: Initial clinical experience



Artificial Organs 18(5): 390-396



Eleven patients were treated with the Hepatix extracorporeal liver assist device (ELAD) between June 1991 and August 1993. The first 2 patients were treated according to Food and Drug Administration guidelines ("Emergency Use of Unapproved Medical Devices," October 22, 1985), and the remaining 9 were treated according to an Investigational Device Exemption (IDE). The goal of the study was to establish the short-term safety of ELAD therapy, with a focus on acute medical complications such as hemodynamic instability, complement activation, and deterioration of vital organ function. As secondary goals, the metabolic capacity of ELAD cartridges and their clinical impact were assessed. Treatment was considered successful if the patient recovered sufficient liver function to survive weaning from the ELAD or was stabilized until orthotopic liver transplantation was performed. No short-term safety problems were associated with ELAD use. In addition, metabolic support was documented in 10 of the 11 patients, and 6 patients reached a successful end-point. The Hepatix ELAD is safe, and it provides measurable metabolic support in patients with late-stage liver failure. This pilot study provides the impetus to perform controlled trials of ELAD therapy in the treatment of various types of end-stage liver disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009583238

Download citation: RISBibTeXText

PMID: 8037614

DOI: 10.1111/j.1525-1594.1994.tb02221.x


Related references

Initial clinical experience with the extracorporeal liver assist device. International Journal of Artificial Organs 23(8): 535, 2000

The hepatix extracorporeal liver assist device in the treatment of fulminant hepatic failure. Asaio Journal 40(1): 83-85, 1994

Use of the Hepatix Extracorporeal Liver Assist Device in the treatment of fulminant hepatic failure. Hepatology 18(4 Part 2): 65A, 1993

A controlled trial of the hepatix extracorporeal liver assist device in acute liver failure. Hepatology 20(4 Part 2): 140A, 1994

The hepatix extracorporeal liver assist device in the treatment of fulminant hepatic failure Results in the first eleven patients. Gastroenterology 106(4 Suppl. ): A29, 1994

Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation 74(12): 1735-1746, 2002

Initial clinical experience with a new cardiac assist device the pulsatile assist device. Chest 70(3): 420, 1976

Clinical experience with a pumpless extracorporeal lung assist device. Anaesthesia 63(11): 1241-1244, 2008

Clinical experience with the iLA Membrane Ventilator pumpless extracorporeal lung-assist device. Expert Review of Medical Devices 4(3): 297-305, 2007

Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study. Journal of Hepatology 63(3): 634-642, 2015

Initial clinical experience with a new temporary left ventricular assist device. Annals of Thoracic Surgery 29(1): 66-69, 1980

Initial clinical experience with the hemopump left ventricular assist device. Australian & New Zealand Journal of Surgery 61(4): 271-275, 1991

The Thoratec Implantable Ventricular Assist Device (IVAD): initial clinical experience. Heart Surgery Forum 9(4): E690-E692, 2006